RxDoctor Payments Data

Unni Thomas, MD

Hematology & Oncology · Jacksonville, FLNPI 1851388573

Payments from drug & device makers

$2,999in general payments, 2019–2025

Across 105 payments — averaging $28.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$360
  • Daiichi Sankyo Inc.$330
  • GSK$299
  • Sobi, Inc$192
  • Sanofi$150
  • Exelixis Inc.$147
  • plus $2K from 42 others

What the payments were for

  • Food & beverage$2,97499%
  • Education$241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,999 in reported general payments places this provider in the 30th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$2,304,770
Medicare patients
521
Services billed
128,595

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SprycelDasatinib12$253,553
ImbruvicaIbrutinib11$178,599
RevlimidLenalidomide11$139,349
Lenalidomide13$115,677
JakafiRuxolitinib Phosphate11$95,163
EliquisApixaban96$69,315
GleevecImatinib Mesylate12$66,337
Abiraterone Acetate19$21,877
Letrozole81$1,196
ValacyclovirValacyclovir Hcl28$989
Tamoxifen Citrate45$893
Hydroxyurea25$621
Oxycodone Hcl63$564
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen22$450
Pregabalin15$282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Sprycel$360$253,55312 claims
Incyte CorporationJakafi$70$95,16311 claims
PfizerEliquis$96$69,31596 claims
NovartisGleevec$120$66,33712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →